StonksNews

0auto
  • price
  • Marketcap$ 585.04 m
  • Week52high$ 5.85
  • Week52low$ 2.88
  • Avg10volume$ 986.45 k
  • Peratio$ 0.00
  • Sharesoutstanding$ 103.36 m
  • Beta$ 1.24
  • Month1changepercent$ 0.17

Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and other neurological and neuromuscular disorders. Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ('FDA'), and Firdapse is now commercially available in the United States. Further, Canada's national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.